Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astellas Pharma Inc
(OP:
ALPMF
)
12.00
UNCHANGED
Streaming Delayed Price
Updated: 1:09 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astellas Pharma Inc
< Previous
1
2
Next >
Astellas - Seagen's Padcev Approved In Europe For Most Common Form Of Bladder Cancer
April 13, 2022
The
Via
Benzinga
Astellas' Menopause Drug Suffers Setback After Failed Asian Trial
March 15, 2022
Via
Benzinga
Astellas Touts Safety Data For Phase 3 Menopause Drug, Sets Up US Filing
March 07, 2022
Astellas Pharma Inc (OTC: ALPMF) announced topline results from the Phase 3 SKYLIGHT 4 trial investigating the long-term safety of fezolinetant in vasomotor...
Via
Benzinga
Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients
February 15, 2022
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) announced the initial results from Cohort H of the EV-103 trial investigating PADCEV (...
Via
Benzinga
Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact
December 02, 2021
Gene therapy startup Dyno Therapeutics Inc has partnered with pharmaceutical giants such as Novartis AG (NYSE: NVS) and Roche Holdings AG (OTC: RHHBY...
Via
Benzinga
Astellas Pharma's Bladder Cancer Treatment Scores Approval In Japan
September 27, 2021
Japan's Ministry of Health, Labor, and Welfare (MHLW) has approved Astellas Pharma Inc's (OTC: ALPMF) Padcev (enfortumab vedotin) for radically...
Via
Benzinga
Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold
September 14, 2021
Astellas Pharma Inc (OTC: ALPMF) has seen the fourth death in its experimental gene therapy trial gained through a $3 billion buyout of Audentes Therapeutics...
Via
Benzinga
Exposures
Product Safety
See Why Astellas Stopped Dosing In Neuromuscular Disease Gene Therapy Trial
September 01, 2021
Astellas Pharma Inc (OTC: ALPMF) has voluntarily paused screening and dosing of additional participants in its ASPIRO trial evaluating AT132 gene therapy in...
Via
Benzinga
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
August 20, 2021
The European Commission (EC) has approved FibroGen Inc (NASDAQ: FGEN) and Astellas Pharma's (OTC: ALPMF) Evrenzo (roxadustat) for anemia caused by...
Via
Benzinga
Exposures
Product Safety
FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial
August 11, 2021
The FDA has issued a complete response letter regarding the marketing application for FibroGen Inc's (NASDAQ: FGEN) roxadustat for anemia of chronic kidney disease...
Via
Benzinga
Exposures
Product Safety
Astellas - Seagen's PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer
July 12, 2021
The FDA granted full approval and a label expansion for Seagen Inc (NASDAQ: SGEN) - Astellas Pharma Inc's (OTC: ALPMF) PADCEV to treat...
Via
Benzinga
Exposures
Product Safety
Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows
May 11, 2021
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has reported first preclinical data from its HiT targeting mesothelin (a tumor-associated antigen), being co-...
Via
Benzinga
Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics
May 03, 2021
Cytokinetics Inc (NASDAQ: CYTK) revealed in an SEC filing that Astellas Pharma Inc (OTCMKTS: ALPMY) is walking away from a pact to research and...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Astellas Takes $540M Impairment Charge Of $3B Audentes Buyout On Gene Therapy Trial Hold
April 27, 2021
In a financial notice posted earlier today, Astellas Pharma Inc (OTCMKTS: ALPMY) said it was taking an impairment loss of ¥58.8 billion ($540 million) because of...
Via
Benzinga
FibroGen Stock Is Trading Lower As CEO Admits Manipulated Safety Data For Roxadustat
April 07, 2021
FibroGen Inc (NASDAQ: FGEN) stock plummeted after hours on Tuesday after a murky disclosure for roxadustat, the company’s anemia treatment in chronic kidney...
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.